Abstract
Alzheimer’s disease (AD) is a looming public health crisis that currently lacks an effective treatment. Noninvasive Brain Stimulation (NBS), particularly transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offers a promising alternative approach to pharmacological interventions for an increasing number of neurological and psychiatric conditions. The aim of this review is summarize data from therapeutic trials of NBS in AD and other dementing illnesses.
Despite the potential of NBS, there is limited theoretical framework and a lack of guidelines for its applications to AD. Several published clinical trials failed to report key parameters of the interventions thus limiting the utility of the study to assess efficacy and safety. Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials. Ultimately, appropriately powered, and controlled, multi-site randomized clinical trials will be needed to evaluate the therapeutic potential of NBS in AD.Keywords: Alzheimer's disease, transcranial magnetic stimulation, TMS, tDCS, dementia, noninvasive brain stimulation, NBS.
Current Alzheimer Research
Title:Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease
Volume: 14 Issue: 4
Author(s): Irene Gonsalvez, Roey Baror, Peter Fried, Emiliano Santarnecchi and Alvaro Pascual-Leone
Affiliation:
Keywords: Alzheimer's disease, transcranial magnetic stimulation, TMS, tDCS, dementia, noninvasive brain stimulation, NBS.
Abstract: Alzheimer’s disease (AD) is a looming public health crisis that currently lacks an effective treatment. Noninvasive Brain Stimulation (NBS), particularly transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offers a promising alternative approach to pharmacological interventions for an increasing number of neurological and psychiatric conditions. The aim of this review is summarize data from therapeutic trials of NBS in AD and other dementing illnesses.
Despite the potential of NBS, there is limited theoretical framework and a lack of guidelines for its applications to AD. Several published clinical trials failed to report key parameters of the interventions thus limiting the utility of the study to assess efficacy and safety. Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials. Ultimately, appropriately powered, and controlled, multi-site randomized clinical trials will be needed to evaluate the therapeutic potential of NBS in AD.Export Options
About this article
Cite this article as:
Gonsalvez Irene, Baror Roey, Fried Peter, Santarnecchi Emiliano and Pascual-Leone Alvaro, Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease, Current Alzheimer Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567205013666160930113907
DOI https://dx.doi.org/10.2174/1567205013666160930113907 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endocannabinoid System and Huntingtons Disease
Current Drug Targets - CNS & Neurological Disorders Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Clinical Applications of MAO-Inhibitors
Current Medicinal Chemistry Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Approaches to a Multitargeting Drug Development: First Profiled 3- Ethoxycarbonyl-1-aza-9-oxafluorenes Representing a Perspective Compound Class Targeting Alzheimer Disease Relevant Kinases CDK1, CDK5 and GSK-3β
Medicinal Chemistry Catatonia: A Brief Update
Current Psychiatry Reviews A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology Editorial [Hot Topic:Fluorine-Containing Drugs as PET Diagnostics (F-18 Labeled Tracers)]
Current Topics in Medicinal Chemistry From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology Hormones in the Mentally Disturbed Brain: Steroids and Peptides in the Development and Treatment of Psychopathology
Central Nervous System Agents in Medicinal Chemistry Blood Coagulation and the Risk of Atherothrombosis
Current Genomics Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Computational Drug Repositioning for Cancer Therapeutics
Current Topics in Medicinal Chemistry Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics
Current Alzheimer Research Persistent Psychosis from Toluene Exposure; More Likely Coincidence than Cause: A Review of our Experience and the Literature
Current Psychiatry Reviews Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design Geniposide Attenuates Mitochondrial Dysfunction and Memory Deficits in APP/PS1 Transgenic Mice
Current Alzheimer Research